Skip to main content
Premium Trial:

Request an Annual Quote

EXCLUSIVE: Genometrix Ceases Operations, Holds onto Hope of Restarting

NEW YORK, July 6 – Out of cash, Genometrix ceased operations as of Monday, June 25, a company official told GenomeWeb.

The Woodlands, Texas-based company laid off approximately 35 employees, leaving the company with a skeleton staff of five people, said David Jorden, CFO. On that day, companies using Genometrix products were told that the company had “stopped pursuing to completion existing service contracts,” said Jorden.

The company, which is currently seeking additional capital, will either “proceed with formal dissolution of the business, including sale to interested parties of assets,” or return to business with additional private funding.

Jorden estimated that the company would need approximately $10 million to remain solvent for about two-and-a-half years.

“We’ll know within two weeks whether we have a realistic option of restarting the company,” said Jorden. “If we end up on the path to liquidation, in five to eight weeks it will be consummated.”

“We think the technology has some real value,” added Jorden. “The best prospect for all considered would be a restart, but we can make no guarantees.”

The company, which developed custom-designed and prefabricated microarrays as well as software tools used to analyze gene expression data, withdrew its application for an initial public offering in February.

According to the company's original S-1 filing, Genometrix had $6.5 million cash and cash equivalents at the end of December 1999. In February 2001, a Genometrix spokesperson said that the company had not raised additional money since the filing.  

Motorola holds a 16.4 percent stake in Genometrix, according to an SEC filing. While a Motorola spokesperson confirmed that Motorola was aware of rumors of Genometrix’s closing, it had not yet received documentation and thus would not comment.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.